WO1992000099A1 - Method of introducing a peptide into the cytosol - Google Patents

Method of introducing a peptide into the cytosol Download PDF

Info

Publication number
WO1992000099A1
WO1992000099A1 PCT/NO1991/000093 NO9100093W WO9200099A1 WO 1992000099 A1 WO1992000099 A1 WO 1992000099A1 NO 9100093 W NO9100093 W NO 9100093W WO 9200099 A1 WO9200099 A1 WO 9200099A1
Authority
WO
WIPO (PCT)
Prior art keywords
toxin
peptide
cytosol
mutant
cells
Prior art date
Application number
PCT/NO1991/000093
Other languages
French (fr)
Inventor
Sjur Olsnes
Original Assignee
Forskningsstiftelsen Det Norske Radiumhospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forskningsstiftelsen Det Norske Radiumhospital filed Critical Forskningsstiftelsen Det Norske Radiumhospital
Priority to AU80001/91A priority Critical patent/AU653158C/en
Priority to JP3510777A priority patent/JPH06503552A/en
Publication of WO1992000099A1 publication Critical patent/WO1992000099A1/en
Priority to FI925869A priority patent/FI925869A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Definitions

  • the present invention is directed to a method of in- troducing a peptide into the cytosol, and more specifically to a novel principle in vaccine production against viruses, intracellular parasites and bacteria and against malignant cells.
  • MHC histocompati- bility antigens
  • MHC Class I MHC Class I
  • the common way today to immunize against such structures is to use attenuated live viruses that are able to enter cells and replicate such that the peptides in question are formed in the cells and can be presented at the cell surface. In this way the population of the relevant cytotoxic CD8 + cells is expanded and upon later exposure to the corres ⁇ ponding virulant virus strain, the organism has an immune protection.
  • toxin molecules that are of very low toxicity (Barbieri, J.T. & Collier, R.J. Infect. Immun. 55, 1647-1651 (1987)). If the toxins were able to carry s into cells additional peptide material, such non-toxic mutants could be useful for vaccine purposes to carry into the cytosol antigenic peptides (Cerundolo et al. Nature 345, 449 (1990)) that can be presented by Class I MHC antigens. Such antigenic sequences can be obtained from a number of viruses, bacteria o and parasites, and it is also possible to derive such struc ⁇ tures from certain malignant cells.
  • the present invention relates to a method of introducing a peptide into the cytosol by linking the peptide to a bacterial or plant toxin, or a mutant thereof. Further, the present invention relates to a method of preparing a vaccine by linking a peptide to a bacterial or plant toxin, or a mutant thereof to translocate the peptide into the cytosol for subsequent presentation at the cell surface by Class I MHC antigens to elicit a Class I restricted immune response and to expand the relevant population of CD8 + T-lymphocytes. Also, the present invention relates to vaccines which have been produced by the above-mentioned method, as well as the use of such vaccines against viruses, intracellular bacteria and para ⁇ sites, and against molecules associated with malignancies.
  • FIG. 1 N-terminal extensions of diphtheria toxin.
  • pBD-lS The coding region of the diphtheria toxin gene carrying a triple mutation changing Glu 148 to Ser, and where Gly 1 was replaced by initiator Met placed behind a T3 promotor to give pBD-lS (McGill, S., Stenmark, H., Sandvig, K. & Olsnes, S. : EMBO J. 8, 2843-2848 (1989)).
  • pBD-1 was cleaved with Ncol, and an oligonucleotide encoding the oligopeptide MGVDEYNEMPMPVN (referred to as B3) was inserted.
  • pGD-2 encodes diphtheria toxin with its natural signal sequence, MSRKLFASILIGALLGIGAPPSAHA (referred to as ss), after an SP6 promotor.
  • the plasmid was obtained by digesting pGD-1 (McGill, S., Stenmark, H., Sandvig, K. & Olsnes, S.: EMBO J. 8, 2843-2848 (1989)) with Hindlll and Pstl, removing the overhangs with S x -nuclease and religating to form pGD-2.
  • FIG. 2 Translocation to the cytosol of A-fragment with N-terminally added B3 oligopeptide.
  • pBD-1 and pB-B3-Dl were transcribed and translated in vitro.
  • the corresponding trans ⁇ lation products (DT and B3-DT) were added to Vero cells grow ⁇ ing as monolayers in 24-well microtiter plates and kept at 24°C for 20 min in the presence of 10 ⁇ M monensin (McGill, S., Stenmark, H., Sandvig, K. & Olsnes, S.: EMBO J. 8, 2843-2848 (1989)).
  • the cells were washed twice with Hepes medium and subsequently treated with 0.4 ⁇ g/ml TPCK (N-tosyl-L-phenyl- alanine chloromethyl ketone)-treated trypsin in Hepes medium containing 10 ⁇ M monensin for 5 min at 20°C.
  • the cells were washed and exposed to Hepes medium, pH 4.43, containing 10 mM Na-gluconate to increase the buffering capacity at the low pH. After 2 min at 37°C, the cells were washed with Hepes medium, pH 7.4, and then treated with 3 mg/ml pronase in Hepes medium, pH 7.4, containing 10 ⁇ M monensin for 5 min at 37°C.
  • TPCK N-tosyl-L-phenyl- alanine chloromethyl ketone
  • the cells which were detached from the plastic by the treatment, were recovered by centrifugation and washed once with Hepes medium containing 1 mM NEM (N-ethyl maleimide) and 1 mM PMSF (phenylmethylsulfonyl fluoride).
  • NEM N-ethyl maleimide
  • PMSF phenylmethylsulfonyl fluoride
  • the cells were lysed with Triton X-100 in phosphate buffered saline containing 1 mM PMSF and 1 mM NEM, nuclei were removed by centrifugation and the protein in the supernatant fraction was precipitated with 10% (w/v) trichloroacetic acid or immunoprecipitated with anti-B3 antibodies adsorbed to protein A-Sepharose.
  • FIG.3 Translocation to the cytosol of diphtheria toxin with signal sequence.
  • lane 3 the cells were treated as in lane 2, except that 6 times more translation product was used and the cells were then exposed to pH 4.8 and pronase as in Fig. 2.
  • the cells were lysed with Triton X-100 and the nuclei were removed.
  • the lysed cells were either analyzed with non-reducing SDS-PAGE (15% gel) directly (lanes 5-8) or they were treated with saponin and the membrane pellets (lanes 9 and 10) and the supernatant fractions (lanes 11 and 12) were analyzed separately.
  • Diphtheria toxin is synthesized by pathogenic strains of Corynebacterium diphtheriae as a single chain polypeptide.
  • the protein is easily split ( “nicked” ) at a trypsin-sensitive site to yield two disulfide-linked fragments, A and B (Pappen- heimer, A.M., Jr. Annu. Rev. Biochem. 46, 69-94 (1977)).
  • the B-fragment (37 kD) binds to cell surface receptors
  • the A-fragment (21 kD) is an enzyme that is trans ⁇ located to the cytosol where it inactivates elongation factor 2 by ADP-ribosylation and thus blocks protein synthesis (Van Ness, B.G., Hovard, J.B. & Bodley, J.W. J. Biol. Chem. 255, 10710-10716 (1980)).
  • the translocation which normally occurs across the limiting membrane of endosomes, is triggered by the low pH in the acidic vesicles (Draper, R.K. & Simon, M.I. J. Cell Biol.
  • a mutant toxin which contains a triple mutation changing Glu 148 , which is located in the enzymatically active site of the toxin, to Ser (Barbieri, J. T. & Collier, R.J. Infect. Immun. 55, 1647-1651 (1987)).
  • the modified toxin has strongly reduced toxicity.
  • toxin with B3 was selectively precipitated with anti-B3 (lane 4), but not with a control serum (lane 5). Toxin without B3 was not precipitated with anti-B3 (lane 3).
  • the dialyzed translation products were bound to Vero cells, nicked on the cells with low concentrations of trypsin, and then the cells were exposed to pH 4.8. Under these conditions part of the bound toxin was translocated to the cytosol and thereby became shielded against pronase added to s the medium (Moskaug, 3.0. , Sandvig, K. & Olsnes, S. J. Biol. Chem. 263, 2518-2525 (1988)). In the case of diphtheria toxin as such, two fragments (MW 21 kD and 25 kD) were protected under these conditions (Fig.
  • toxin carrying its normal signal sequence (25 amino acids). As shown in Fig. 3, lane 2, this protein was nicked by trypsin into a 23.5 kD A-fragment and a 37 kD B- fragment. (In this experiment the toxin was only partially nicked. Partially nicked 125 I-labelled natural toxin is shown for comparison in lane 1). When the toxin with signal sequence was bound to cells, nicked, and then exposed to pH 4.8, two fragments (23.5 kD and 25 kD) were protected against pronase (lane 8).
  • Protected A-fragment with uncleaved signal sequence is also shown in lane 3, where the material was precipitated with an anti-diphtheria toxin serum which binds the whole toxin, the A-fragment, as well as whole B-fragment (see lanes 1 and 2), but not the 25 kD-fragment.
  • the pronase-treated cells were treated with saponin, the extended A-fragment was released to the medium (lanes 4 and 12), whereas the 25 kD fragment remained in the membrane fraction (lane 10).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A method of introducing a peptide into the cytosol by linking the peptide to a bacterial or plant toxin, or a mutant thereof. A method of preparing a vaccine by linking a peptide to a bacterial or plant toxin, or a mutant thereof to translocate the peptide into the cytosol for subsequent presentation at the cell surface by Class I MHC antigens to elicit a Class I restricted immune response and to expand the relevant population of CD8+ T-lymphocytes. Vaccines produced by said method and the use thereof against viruses, intracellular bacteria and parasites, and against molecules associated with malignancies.

Description

Method of introducing a peptide into the cytosol
Field of the Invention
The present invention is directed to a method of in- troducing a peptide into the cytosol, and more specifically to a novel principle in vaccine production against viruses, intracellular parasites and bacteria and against malignant cells.
Background of the Invention
In the protection against pathogenic organisms and in their elimination antigen presentation by major histocompati- bility antigens (MHC) of class I plays an important role. Cytotoxic T-lymphocytes recognize cells that express foreign or unusual antigens on their surface and destroy the cells, which is important to eliminate an infection. The same mechan¬ ism is operating in the elimination of malignant cells. Anti¬ gen presentation by Class I MHC requires that the antigen to be presented is found in the cytosol or in the endoplasmic reticulum (Germain, R.N. Nature 322, 687-689 (1986)). Extern¬ ally added polypeptides therefore do normally not elicit a class I response. However, if the antigen is artificially introduced into the cytosol, presentation by MHC Class I may occur (Moore, M.W., Carbone, F.R. & Bevan, M.J. Cell 54, 777- 785 (1988)). The common way today to immunize against such structures is to use attenuated live viruses that are able to enter cells and replicate such that the peptides in question are formed in the cells and can be presented at the cell surface. In this way the population of the relevant cytotoxic CD8+ cells is expanded and upon later exposure to the corres¬ ponding virulant virus strain, the organism has an immune protection. The problems with this approach are partly due to the fact that the attenuated viruses may sometimes revert to virulence and partly to the problems of making attenuated viruses in many cases. Convenient and non-damaging methods to introduce into the cytosol foreign peptides, such as viral antigens, could therefore be useful for vaccine purposes to expand the relevant population of CD8+ MHC Class I restricted cytotoxic T-lymphocytes. The only established examples of external proteins that enter the cytosol are certain bacterial and plant toxins, such as diphtheria toxin, Pseudomonas aeruqinosa exotoxin A, ricin, abrin, viscumin, modeccin, Shigella toxin, cholera toxin,
5 pertussis toxin (Olsnes, S. & Sandvig, K. In: "Immunotoxins" (A.E. Frankel, ed.), Kluwer Academic Publishers, Boston 1988, pp. 39-73; Olsnes, S. & Sandvig, K. In "Receptor-mediated endocytosis" (I. Pastan & M.C. Willingham, eds.), Plenum Publ. Corp., 1985, pp. 195-234). Toxins of this group enter the o cytosol where they carry out enzymatic reactions that are deleterious to the cell or to the organism. By gene manipu¬ lations it is possible to form toxin molecules that are of very low toxicity (Barbieri, J.T. & Collier, R.J. Infect. Immun. 55, 1647-1651 (1987)). If the toxins were able to carry s into cells additional peptide material, such non-toxic mutants could be useful for vaccine purposes to carry into the cytosol antigenic peptides (Cerundolo et al. Nature 345, 449 (1990)) that can be presented by Class I MHC antigens. Such antigenic sequences can be obtained from a number of viruses, bacteria o and parasites, and it is also possible to derive such struc¬ tures from certain malignant cells.
It is an object of the present invention to provide a mechanism of translocating antigenic peptide sequences to the 5 cytosol in a safe way to expand the population of cytotoxic T- lymphocytes that are able to react with the corresponding antigen and eliminate those cells that are presenting the antigenic peptides. Although the entry mechanism for the different toxins mentioned above is in principle the same, it o has been worked out in most detail in the case of diphtheria toxin. This is the toxin we have used in most of our studies in connection with this application.
Summary of the Invention 5 we here demonstrate that an essentially non-toxic mutant of diphtheria toxin is able to translocate to the cyto¬ sol oligopeptides linked to its N-terminal end. The peptides we have studied are sufficiently different in sequence to allow the conclusion that a wide variety of peptides can be carried into the cells in the same way.
Thus, the present invention relates to a method of introducing a peptide into the cytosol by linking the peptide to a bacterial or plant toxin, or a mutant thereof. Further, the present invention relates to a method of preparing a vaccine by linking a peptide to a bacterial or plant toxin, or a mutant thereof to translocate the peptide into the cytosol for subsequent presentation at the cell surface by Class I MHC antigens to elicit a Class I restricted immune response and to expand the relevant population of CD8+ T-lymphocytes. Also, the present invention relates to vaccines which have been produced by the above-mentioned method, as well as the use of such vaccines against viruses, intracellular bacteria and para¬ sites, and against molecules associated with malignancies.
Figure Legends
FIG. 1. N-terminal extensions of diphtheria toxin.
A. The coding region of the diphtheria toxin gene carrying a triple mutation changing Glu148 to Ser, and where Gly1 was replaced by initiator Met placed behind a T3 promotor to give pBD-lS (McGill, S., Stenmark, H., Sandvig, K. & Olsnes, S. : EMBO J. 8, 2843-2848 (1989)). To obtain pB-B3-Dl, pBD-1 was cleaved with Ncol, and an oligonucleotide encoding the oligopeptide MGVDEYNEMPMPVN (referred to as B3) was inserted. pGD-2 encodes diphtheria toxin with its natural signal sequence, MSRKLFASILIGALLGIGAPPSAHA (referred to as ss), after an SP6 promotor. The plasmid was obtained by digesting pGD-1 (McGill, S., Stenmark, H., Sandvig, K. & Olsnes, S.: EMBO J. 8, 2843-2848 (1989)) with Hindlll and Pstl, removing the overhangs with Sx-nuclease and religating to form pGD-2.
B. The genes were transcribed in vitro and the mRNAs obtained were translated in rabbit reticulocyte lysate systems in the presence of [35S]methionine (McGill, S., Stenmark, H., Sandvig, K. & Olsnes, S.: EMBO J. 8, 2843-2848 (1989)). To remove reducing agents and to allow disulfide bridges to be formed, the translation mixture was dialyzed over night against PBS (0.14 M NaCl, 10 mM Na-phosphate, pH 7.4), and then for 4 h against Hepes medium (Dulbecco-modified Eagles medium wherein the bicarbonate had been replaced by 20 mM Hepes, pH 7.4). An aliquot of each sample was analyzed by polyacrylami.de gel electrophoresis in the presence of sodium dodecyl sulfate (SDS-PAGE) under reducing conditions (Olsnes, S. & Eiklid, K. J. Biol. Chem. 255, 284-289 (1980)). In some cases the translation product was treated with protein A- Sepharose (Pharmacia, Sweden), which had previously been incubated with rabbit anti-B3 antiserum (lanes 3 and 4) or anti-ricin (lane 5). The adsorbed material was analyzed by SDS-PAGE. DT, translation product from pBD-1; B3-DT, trans¬ lation product from pB-B3-Dl; ss-DT, translation product from pGD-2.
FIG. 2. Translocation to the cytosol of A-fragment with N-terminally added B3 oligopeptide. pBD-1 and pB-B3-Dl were transcribed and translated in vitro. The corresponding trans¬ lation products (DT and B3-DT) were added to Vero cells grow¬ ing as monolayers in 24-well microtiter plates and kept at 24°C for 20 min in the presence of 10 μM monensin (McGill, S., Stenmark, H., Sandvig, K. & Olsnes, S.: EMBO J. 8, 2843-2848 (1989)). The cells were washed twice with Hepes medium and subsequently treated with 0.4 μg/ml TPCK (N-tosyl-L-phenyl- alanine chloromethyl ketone)-treated trypsin in Hepes medium containing 10 μM monensin for 5 min at 20°C. The cells were washed and exposed to Hepes medium, pH 4.43, containing 10 mM Na-gluconate to increase the buffering capacity at the low pH. After 2 min at 37°C, the cells were washed with Hepes medium, pH 7.4, and then treated with 3 mg/ml pronase in Hepes medium, pH 7.4, containing 10 μM monensin for 5 min at 37°C. The cells, which were detached from the plastic by the treatment, were recovered by centrifugation and washed once with Hepes medium containing 1 mM NEM (N-ethyl maleimide) and 1 mM PMSF (phenylmethylsulfonyl fluoride). In some cases, (lanes 1-3 and 8-10) the cells were lysed with Triton X-100 in phosphate buffered saline containing 1 mM PMSF and 1 mM NEM, nuclei were removed by centrifugation and the protein in the supernatant fraction was precipitated with 10% (w/v) trichloroacetic acid or immunoprecipitated with anti-B3 antibodies adsorbed to protein A-Sepharose. In other cases (lanes 4-7) the cells were treated with 50 μg/ml saponin in PBS containing 1 mM PMSF and 1 mM NEM to release translocated A-fragment, and then the proteins both in the pellet and in the supernatant fractions were precipitated with trichloroacetic acid. In all cases the precipitated material was analyzed by SDS-PAGE (13.5% gel) under non-reducing conditions.
FIG.3. Translocation to the cytosol of diphtheria toxin with signal sequence. Lanes 1-4: 125I-labelled natural toxin (wt-DT, lane 1) and in vitro translated pGD-2 ( [35S]methionine labelled toxin with signal sequence, ss-DT) were bound to Vero cells and nicked on the cells (lanes 1 and 2). In lane 3 the cells were treated as in lane 2, except that 6 times more translation product was used and the cells were then exposed to pH 4.8 and pronase as in Fig. 2. The cells were lysed with Triton X-100 and the nuclei were removed. The supernatants were incubated with protein A-sepharose that had been pre- incubated with rabbit anti-diphtheria toxin serum. The adsorb¬ ed material was analyzed by reducing (lanes 1 and 2) or non- reducing (lanes 3 and 4) SDS-PAGE (10% gel). In lane 4 the pronase-treated cells were treated with 50 μg/ml saponin and the material released to the medium was analyzed directly. Lanes 5-12: Translation products from pBD-1 (DT) and pGD-2 (ss-DT) were bound to Vero cells, nicked, exposed to pH 4.8 and then treated with pronase. The lysed cells were either analyzed with non-reducing SDS-PAGE (15% gel) directly (lanes 5-8) or they were treated with saponin and the membrane pellets (lanes 9 and 10) and the supernatant fractions (lanes 11 and 12) were analyzed separately.
Detailed Description Diphtheria toxin is synthesized by pathogenic strains of Corynebacterium diphtheriae as a single chain polypeptide. The protein is easily split ( "nicked" ) at a trypsin-sensitive site to yield two disulfide-linked fragments, A and B (Pappen- heimer, A.M., Jr. Annu. Rev. Biochem. 46, 69-94 (1977)). The B-fragment (37 kD) binds to cell surface receptors, whereas the A-fragment (21 kD) is an enzyme that is trans¬ located to the cytosol where it inactivates elongation factor 2 by ADP-ribosylation and thus blocks protein synthesis (Van Ness, B.G., Hovard, J.B. & Bodley, J.W. J. Biol. Chem. 255, 10710-10716 (1980)). The translocation, which normally occurs across the limiting membrane of endosomes, is triggered by the low pH in the acidic vesicles (Draper, R.K. & Simon, M.I. J. Cell Biol. 87, 849-854 (1980); Sandvig, K. & Olsnes, S. ___ s Cell Biol. 87, 828-832 (1980)). When cells with surface-bound toxin are exposed to acidic medium, translocation occurs from the cell surface (Sandvig, K. & Olsnes, S. J. Biol. Chem. 256, 9068-9076 (1981) ). We have in the presented examples used this artificial system, because it enables us to distinguish o between translocated and non-translocated material (Moskaug, 3.0. , Sandvig, K. & Olsnes, S. J. Biol. Chem. 262, 10339-10345 (1987); Moskaug, J.0., Sandvig, K. & Olsnes, S. J. Biol. Chem. 263, 2518-2525 (1988)).
To avoid toxic effect on the cells by the diphtheria s toxin vector, a mutant toxin was used which contains a triple mutation changing Glu148, which is located in the enzymatically active site of the toxin, to Ser (Barbieri, J. T. & Collier, R.J. Infect. Immun. 55, 1647-1651 (1987)). The modified toxin has strongly reduced toxicity. 0
Examples
We used two variants of the mutated toxin gene, one without (pBD-1) (McGill, S., Stenmark, H., Sandvig, K. & Olsnes, S.: EMBO J. 8, 2843-2848 (1989)), and one with (pGD-2) 5 the natural 25 amino acids signal sequence (Fig. 1A). In one case, a foreign oligopeptide, termed B3, was linked to the N- terminal end of the toxin to yield the plasmid pB-B3-Dl.
The constructs, which were placed behind T3 or SP6 RNA- polymerase promotors, were transcribed and translated in vitro o (McGill, S., Stenmark, H., Sandvig, K. & Olsnes, S. :EMBO J. 8, 2843-2848 (1989)). In each case a major band corresponding to the full-length protein and only traces of material of lower molecular weights were obtained (Fig. IB). Toxin with signal sequence (lane 7) or with B3 (lane 1) migrated, as expected, 5 slightly more slowly than toxin as such (lanes 2 and 6).
Furthermore, toxin with B3 was selectively precipitated with anti-B3 (lane 4), but not with a control serum (lane 5). Toxin without B3 was not precipitated with anti-B3 (lane 3).
The dialyzed translation products were bound to Vero cells, nicked on the cells with low concentrations of trypsin, and then the cells were exposed to pH 4.8. Under these conditions part of the bound toxin was translocated to the cytosol and thereby became shielded against pronase added to s the medium (Moskaug, 3.0. , Sandvig, K. & Olsnes, S. J. Biol. Chem. 263, 2518-2525 (1988)). In the case of diphtheria toxin as such, two fragments (MW 21 kD and 25 kD) were protected under these conditions (Fig. 2, lane 1), corresponding to the whole A-fragment (21 kD) and part of the B-fragment (25 kD out o of total 37 kD). The interfragment disulfide was reduced, apparently upon exposure to the cytosol (Moskaug, 3.0. , Sandvig, K. & Olsnes, S. J. Biol. Chem. 262, 10339-10345 (1987)).
s Example 1
When the same experiment was carried out with toxin containing B3, two major fragments (25 kD and 22.5 kD) were protected in addition to small amounts of 21 kD fragment (lane 2). The latter probably represents A-fragment where B3 had o been cleaved off. When the exposure to low pH was omitted, no fragments were protected (lane 3). The 22.5 kD fragment was precipitated by anti-B3 (lane 9), but not with preimmune serum (lane 10). Protected A-fragment without the oligopeptide was not precipitated with anti-B3 (lane 8). The apparently higher 5 amount of protected A-fragment with B3 is due to more radio¬ activity incorporated, as B3 contains 3 methionines and the A- fragment alone 5.
When cells with translocated diphtheria toxin are treated with low concentration of saponin allowing cytoplasmic marker enzymes to leak out of the cells without dissolving the membranes, the translocated A-fragment is released into the medium, whereas the B-fragment-derived 25 kD polypeptide remains associated with the membrane fraction (Moskaug, 3.0. , Sandvig, K. & Olsnes, S. J. Biol. Chem. 263, 2518-2525 (1988); Moskaug, J.0., Sletten, K. , Sandvig, K. & Olsnes, S. J. Biol. Chem. 264, 15709-15713 (1989); Moskaug, J.0., Sandvig, K. & Olsnes, S. J. Biol. Chem. 264, 11367-11372 (1989)). This indi¬ cates that the translocated A-fragment is free in the cytosol, whereas the 25 kD polypeptide is inserted into the membrane. Also most of the A-fragment containing B3 was released with saponin (lane 7) in the same way as normal A-fragment (lane 6), whereas the 25 kD fragment was associated with the membranes (lanes 4 and 5). Therefore, it appears that diph- theria toxin is able to translocate B3 (14 amino acids) to the cytosol.
Example 2
To test if also a larger oligopeptide could be trans- located, we chose toxin carrying its normal signal sequence (25 amino acids). As shown in Fig. 3, lane 2, this protein was nicked by trypsin into a 23.5 kD A-fragment and a 37 kD B- fragment. (In this experiment the toxin was only partially nicked. Partially nicked 125I-labelled natural toxin is shown for comparison in lane 1). When the toxin with signal sequence was bound to cells, nicked, and then exposed to pH 4.8, two fragments (23.5 kD and 25 kD) were protected against pronase (lane 8). Protected A-fragment with uncleaved signal sequence is also shown in lane 3, where the material was precipitated with an anti-diphtheria toxin serum which binds the whole toxin, the A-fragment, as well as whole B-fragment (see lanes 1 and 2), but not the 25 kD-fragment. When the pronase-treated cells were treated with saponin, the extended A-fragment was released to the medium (lanes 4 and 12), whereas the 25 kD fragment remained in the membrane fraction (lane 10).

Claims

Claims
1. A method of introducing a peptide into the cytosol, characterized by linking the peptide to a bacterial or plant toxin, or a mutant thereof.
2. A method of preparing a vaccine, characterized by linking a peptide to a bacterial or plant toxin, or a mutant thereof to translocate the peptide into the cytosol for subse¬ quent presentation at the cell surface by Class I MHC antigens to elicit a Class I restricted, immune response and to expand the relevant population of CD8+ T-lymphocytes.
3. The method according to claims 1 or 2, characterized by using a mutant of a bacterial or plant toxin which has been manipulated in such a way that it has lost its toxicity with¬ out having lost the ability to enter the cytosol and to carry additional peptide material into the cytosol.
4. The method according to claims 1 or 2-3, characterized by using a non-toxic mutant of diphtheria toxin or a related toxin such as ricin, abrin, modeccin, viscumin, volkensin, Pseudomonas aeruginosa exotoxin A, Shigella toxin, cholera toxin, E. coli heat labile toxin or pertussis toxin.
5. The method according to claims 1 or 2-4, characterized by using a non-toxic mutant of diphtheria toxin.
6. A vaccine, characterized by having been produced by a method according to claims 2-5.
7. The use of a vaccine according to claim 6 against viruses, intracellular bacteria and parasites, and against molecules associated with malignancies.
PCT/NO1991/000093 1990-06-27 1991-06-26 Method of introducing a peptide into the cytosol WO1992000099A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU80001/91A AU653158C (en) 1990-06-27 1991-06-26 Method of introducing a peptide into the cytosol
JP3510777A JPH06503552A (en) 1990-06-27 1991-06-26 How to introduce peptides into the cytosol
FI925869A FI925869A0 (en) 1990-06-27 1992-12-23 FOERFARANDE FOER INFOERANDE AV EN PEPTID I CYTOSOL

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO902871 1990-06-27
NO902871A NO175188C (en) 1990-06-27 1990-06-27 Process for Preparing a Peptide Conjugate with the ability to penetrate cell cytosol

Publications (1)

Publication Number Publication Date
WO1992000099A1 true WO1992000099A1 (en) 1992-01-09

Family

ID=19893304

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NO1991/000093 WO1992000099A1 (en) 1990-06-27 1991-06-26 Method of introducing a peptide into the cytosol

Country Status (8)

Country Link
EP (1) EP0542756A1 (en)
JP (1) JPH06503552A (en)
CA (1) CA2086342A1 (en)
FI (1) FI925869A0 (en)
HU (1) HUT63061A (en)
LT (1) LTIP835A (en)
NO (1) NO175188C (en)
WO (1) WO1992000099A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5503829A (en) * 1992-04-21 1996-04-02 Institut Pasteur Recombinant mutants for inducing specific immune responses
US5935580A (en) * 1992-04-21 1999-08-10 Institut Pasteur Recombinant mutants for inducing specific immune responses
WO2000009733A1 (en) * 1998-08-13 2000-02-24 The Regents Of The University Of California Intracellular delivery vehicles
US6043057A (en) * 1988-09-16 2000-03-28 Vitec Aktiebolag Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
WO2000048638A2 (en) * 1999-02-16 2000-08-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
EP1254156A1 (en) * 2000-01-27 2002-11-06 Loma Linda University Transgenic plant-based vaccines
US6777546B2 (en) 1997-10-07 2004-08-17 Loma Linda University Methods and substances for preventing and treating autoimmune disease
JP2006022111A (en) * 1992-02-19 2006-01-26 Scripps Res Inst:The In vitro activation of cytotoxic t cell
WO2007062832A2 (en) * 2005-11-30 2007-06-07 Glaxosmithkline Biologicals S.A. Vaccines containing non-live antigenic vectors
US7422747B2 (en) 1997-10-07 2008-09-09 Loma Linda University Transgenic plant-based vaccines
US9370564B2 (en) 2000-09-15 2016-06-21 Institut Pasteur Vectors for molecule delivery to CD11b expressing cells
CN109790545A (en) * 2016-03-10 2019-05-21 约翰·霍普金斯大学 Generate the method and therapeutical uses of the monomer diphtheria toxin fusion protein without aggregation
US11965009B2 (en) 2016-03-10 2024-04-23 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2532850A1 (en) * 1982-09-15 1984-03-16 Pasteur Institut Immunogenic conjugates between a hapten and a carrier molecule derived from a toxin, vaccines comprising them and method for obtaining them
EP0172107A1 (en) * 1984-08-10 1986-02-19 Praxis Biologics, Inc. Immunogenic conjugates of E. coli LT-B enterotoxin subunit and capsular polymers
US4675382A (en) * 1982-05-12 1987-06-23 President And Fellows Of Harvard College Hybrid protein
EP0332174A2 (en) * 1988-03-08 1989-09-13 The University Of Wyoming Cell specific cytotoxic agents
WO1990003437A1 (en) * 1988-09-27 1990-04-05 L'universite De L'etat A Liege Proteins for fusing the sub-unit b of the choleraic toxin and heterologous antigen, and nucleic acids encoding them
WO1991009871A1 (en) * 1989-12-22 1991-07-11 Seragen Incorporated Hybrid molecules having translocation region and cell-binding region

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675382A (en) * 1982-05-12 1987-06-23 President And Fellows Of Harvard College Hybrid protein
FR2532850A1 (en) * 1982-09-15 1984-03-16 Pasteur Institut Immunogenic conjugates between a hapten and a carrier molecule derived from a toxin, vaccines comprising them and method for obtaining them
EP0172107A1 (en) * 1984-08-10 1986-02-19 Praxis Biologics, Inc. Immunogenic conjugates of E. coli LT-B enterotoxin subunit and capsular polymers
EP0332174A2 (en) * 1988-03-08 1989-09-13 The University Of Wyoming Cell specific cytotoxic agents
WO1990003437A1 (en) * 1988-09-27 1990-04-05 L'universite De L'etat A Liege Proteins for fusing the sub-unit b of the choleraic toxin and heterologous antigen, and nucleic acids encoding them
WO1991009871A1 (en) * 1989-12-22 1991-07-11 Seragen Incorporated Hybrid molecules having translocation region and cell-binding region

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Dialog Information Services, File 155, Medline 67-91, Dialog Accession No. 07152866, S. McGILL et al.: "Membrane interactions of diphtheria toxin analyzed using in vitro synthesized mutants", & EMBO J Oct 1989, 8 (10), p2843-8. *
Dialog Information Services, File 155, Medline 67-91, Dialog Accession No. 07731463, H. STENMARK et al.: "Peptides fused to the amino-terminal end of diphtheria toxin are translocated to the cytosol", & J CELL BIOL (US) Jun 1991, 113 (5), p1025-32. *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043057A (en) * 1988-09-16 2000-03-28 Vitec Aktiebolag Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
JP2006022111A (en) * 1992-02-19 2006-01-26 Scripps Res Inst:The In vitro activation of cytotoxic t cell
JP4584794B2 (en) * 1992-02-19 2010-11-24 ザ スクリプス リサーチ インスティチュート Activation of cytotoxic T cells in vitro
US5679784A (en) * 1992-04-21 1997-10-21 Institut Pasteur Recombinant mutants for inducing specific immune responses
US5935580A (en) * 1992-04-21 1999-08-10 Institut Pasteur Recombinant mutants for inducing specific immune responses
US5503829A (en) * 1992-04-21 1996-04-02 Institut Pasteur Recombinant mutants for inducing specific immune responses
US7115725B2 (en) 1994-06-08 2006-10-03 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US7422747B2 (en) 1997-10-07 2008-09-09 Loma Linda University Transgenic plant-based vaccines
US6777546B2 (en) 1997-10-07 2004-08-17 Loma Linda University Methods and substances for preventing and treating autoimmune disease
WO2000009733A1 (en) * 1998-08-13 2000-02-24 The Regents Of The University Of California Intracellular delivery vehicles
WO2000048638A3 (en) * 1999-02-16 2001-03-01 Harvard College Multi-mutant diphtheria toxin vaccines
WO2000048638A2 (en) * 1999-02-16 2000-08-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
EP1254156A4 (en) * 2000-01-27 2003-05-21 Univ Loma Linda Transgenic plant-based vaccines
EP1254156A1 (en) * 2000-01-27 2002-11-06 Loma Linda University Transgenic plant-based vaccines
US9370564B2 (en) 2000-09-15 2016-06-21 Institut Pasteur Vectors for molecule delivery to CD11b expressing cells
US10004794B2 (en) 2000-09-15 2018-06-26 Institut Pasteur Vectors for molecule delivery to CD11b expressing cells
WO2007062832A2 (en) * 2005-11-30 2007-06-07 Glaxosmithkline Biologicals S.A. Vaccines containing non-live antigenic vectors
WO2007062832A3 (en) * 2005-11-30 2007-09-07 Glaxosmithkline Biolog Sa Vaccines containing non-live antigenic vectors
CN109790545A (en) * 2016-03-10 2019-05-21 约翰·霍普金斯大学 Generate the method and therapeutical uses of the monomer diphtheria toxin fusion protein without aggregation
US11965009B2 (en) 2016-03-10 2024-04-23 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses

Also Published As

Publication number Publication date
NO175188C (en) 1994-09-14
FI925869A (en) 1992-12-23
HU9204125D0 (en) 1993-04-28
LTIP835A (en) 1995-02-27
AU8000191A (en) 1992-01-23
NO902871L (en) 1991-12-30
CA2086342A1 (en) 1991-12-28
HUT63061A (en) 1993-07-28
JPH06503552A (en) 1994-04-21
NO902871D0 (en) 1990-06-27
FI925869A0 (en) 1992-12-23
EP0542756A1 (en) 1993-05-26
AU653158B2 (en) 1994-09-22
NO175188B (en) 1994-06-06

Similar Documents

Publication Publication Date Title
Antoine et al. Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin
CA2691539C (en) Modified toxins
US8044188B2 (en) Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
Stenmark et al. Peptides fused to the amino-terminal end of diphtheria toxin are translocated to the cytosol.
US8524241B2 (en) Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A
EP2267008B1 (en) Activatable recombinant neurotoxins
CA2138137C (en) Diphtheria toxin vaccines
US5668255A (en) Hybrid molecules having translocation region and cell-binding region
JP3755773B2 (en) Diphtheria toxin vaccine with mutant R domain
US6086900A (en) Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
WO1992000099A1 (en) Method of introducing a peptide into the cytosol
JPH04501051A (en) Recombinant DNA-derived Bordetella toxin subunit analog
Madshus et al. Membrane translocation of diphtheria toxin carrying passenger protein domains
De Haan et al. Enhanced delivery of exogenous peptides into the class I antigen processing and presentation pathway
Nicholls et al. The structure of diphtheria toxin as a guide to rational design
JP2004531230A (en) General carrier for molecules targeting GB3 receptor expressing cells
KLINGENBERG et al. Ability of methotrexate to inhibit translocation to the cytosol of dihydrofolate reductase fused to diphtheria toxin
Madshus et al. Entry of ADP-ribosylating toxins into cells
AU653158C (en) Method of introducing a peptide into the cytosol
Tagge et al. Preproricin Expressed inNicotiana tabacumCellsin VitroIs Fully Processed and Biologically Active
Cabiaux pH-sensitive toxins: interactions with membrane bilayers and application to drug delivery
Stenmark et al. Elimination of the disulphide bridge in fragment B of diphtheria toxin: effect on membrane insertion, channel formation, and ATP binding
O'Keefe Characterization of a full-length, active-site mutant of diphtheria toxin
Lemichez et al. Diphtheria toxin and related fusion proteins: autonomous systems for the delivery of proteins and peptides to the cytosol of eukaryotic cells
Stier A mechanistic study of listeriolysin O containing pH-sensitive liposome mediated escape of protein from the endosomal/lysosomal compartment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO PL RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1991911315

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 925869

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 2086342

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1991911315

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991911315

Country of ref document: EP